Stock Message Boards
ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

QCOR Description — Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals is a biopharmaceutical company focused on the treatment of patients with autoimmune and inflammatory disorders. Co.'s primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of 19 indications, including the treatment of exacerbations of multiple sclerosis in adults, as monotherapy for the treatment of infantile spasms in infants and children, and for several rheumatology related conditions. Co.'s other product is Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Company Name:  Questcor Pharmaceuticals Inc
Website:  www.questcor.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding QCOR:  47
Total Market Value Held by ETFs:  $466,843,431
Total Market Capitalization:  $4,854,000,000
% of Market Cap. Held by ETFs:  9.62%
 ETF   QCOR Weight   QCOR Amount 
 IJR   0.67%   $90,893,350         
 IWM   0.26%   $66,570,443         
 IBB   1.26%   $56,151,203         
 PJP   3.92%   $41,936,657         
 IJT   1.41%   $38,580,578         
 XPH   4.51%   $36,433,417         
 IWO   0.51%   $28,915,865         
 VB   0.26%   $21,481,483         
 VBK   0.41%   $15,119,773         
 IHE   2.27%   $14,330,256         
List of all 47 ETFs holding QCOR »
10 ETFs With Stocks That Insiders Are Buying
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Trade QCOR Now:



Buy (3.33 out of 4)
70th percentile
(ranked higher than approx. 70% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Portfolio Channel

PARTNER NEWS:

Tue, Apr 15, 3:25 PM, Zacks
Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog
Eli Lilly/ Boehringer new drug application (NDA) for their empagliflozin/Tradjenta (linagliptin) combination has been accepted for review by the FDA for type II diabetes.

Tue, Apr 15, 6:54 AM, Zacks
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.

ETFs Holding QCOR | Questcor Pharmaceuticals Inc | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2014, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.